Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 14.40% is 205% above its 5-year average of -13.76%, near the high end of its 5-year range (-23.93%–16.45%).
As of the fiscal period ended Tuesday, June 30, 2026. 40.01% above its 12-month average of 10.28%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 14.40%.
RETURN ON EQUITY (ROE)
14.40%
RETURN ON EQUITY (ROE) AVG TTM
10.28%
RETURN ON EQUITY (ROE) AVG 3Y
-7.22%
RETURN ON EQUITY (ROE) AVG 5Y
-13.76%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+40.01%
CURRENT VS 3Y AVG
+299.32%
CURRENT VS 5Y AVG
+204.63%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 754 covered companies
CURRENT VS SECTOR MEDIAN
+134.28%
vs the sector median at left
Strata Critical Medical, Inc.
Market Cap
$412.28M
Return on Equity (ROE)
14.40%
TTM Avg
10.28%
3Y Avg
-7.22%
5Y Avg
-13.76%
Market Cap
$414.54M
Return on Equity (ROE)
-69.06%
TTM Avg
36.89%
3Y Avg
36.89%
5Y Avg
36.89%
Market Cap
$414.18M
Return on Equity (ROE)
-121.12%
TTM Avg
180.84%
3Y Avg
-1331.02%
5Y Avg
-839.91%
Market Cap
$410.18M
Return on Equity (ROE)
-37.05%
TTM Avg
-58.80%
3Y Avg
-40.96%
5Y Avg
-32.01%
Market Cap
$409.20M
Return on Equity (ROE)
-77.06%
TTM Avg
-61.48%
3Y Avg
-56.03%
5Y Avg
-55.28%
Market Cap
$408.17M
Return on Equity (ROE)
-51.17%
TTM Avg
-29.16%
3Y Avg
-33.45%
5Y Avg
-16.04%
Market Cap
$406.16M
Return on Equity (ROE)
-28.18%
TTM Avg
-0.06%
3Y Avg
10.58%
5Y Avg
10.58%
Market Cap
$406.41M
Return on Equity (ROE)
-43.14%
TTM Avg
2.19%
3Y Avg
15.11%
5Y Avg
15.11%
Market Cap
$420.28M
Return on Equity (ROE)
-65.99%
TTM Avg
-51.25%
3Y Avg
-81.12%
5Y Avg
-81.12%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Strata Critical Medical, Inc. (SRTA) | $412.28M | 14.40% | 10.28% | -7.22% | -13.76% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $414.54M | -69.06% | 36.89% | 36.89% | 36.89% |
| Senseonics Holdings, Inc. (SENS)vs › | $414.18M | -121.12% | 180.84% | -1331.02% | -839.91% |
| Myriad Genetics, Inc. (MYGN)vs › | $410.18M | -37.05% | -58.80% | -40.96% | -32.01% |
| Rezolute, Inc. (RZLT)vs › | $409.20M | -77.06% | -61.48% | -56.03% | -55.28% |
| Neurogene Inc. (NGNE)vs › | $408.17M | -51.17% | -29.16% | -33.45% | -16.04% |
| Shoulder Innovations, Inc. (SI)vs › | $406.16M | -28.18% | -0.06% | 10.58% | 10.58% |
| Carlsmed, Inc. (CARL)vs › | $406.41M | -43.14% | 2.19% | 15.11% | 15.11% |
| MapLight Therapeutics, Inc. (MPLT)vs › | $420.28M | -65.99% | -51.25% | -81.12% | -81.12% |
| Prothena Corporation plc (PRTA)vs › | $420.34M | -15.33% | -56.08% | -39.28% | -33.86% |
ROE
14.4%
ROA
12.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 14.40% |
| 2026-03-31 | 16.45% |
| 2025-12-31 | 14.82% |
| 2025-09-30 | 14.27% |
| 2025-06-30 | -8.51% |
| 2025-03-31 | -12.09% |
| 2024-12-31 | -12.30% |
| 2024-09-30 | -22.04% |
| 2024-06-30 | -21.45% |
| 2024-03-31 | -21.18% |
| 2023-12-31 | -23.93% |
| 2023-09-30 | -14.28% |
| 2023-06-30 | -18.06% |
| 2023-03-31 | -9.88% |
| 2022-12-31 | -9.93% |
| 2022-09-30 | -7.44% |
| 2022-06-30 | -3.77% |
| 2022-03-31 | -15.44% |
| 2021-12-31 | -12.68% |
| 2021-09-30 | -10.33% |
| 2021-06-30 | -10.64% |
| 2021-03-31 | -3.75% |
| 2020-12-31 | -2.92% |
| 2020-09-30 | -42.96% |
| 2020-06-30 | -1.47% |
